Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis

Journal of Clinical Gastroenterology

Volumn 51, Issue 3, 2017, Pages 254-260

  Sayiner, Mehmet ^a   Otgonsuren, Munkhzul ^a   Cable, Rebecca ^a   Younossi, Issah ^b   Afendy, Mariam ^a   Golabi, Pegah ^a   Henry, Linda ^b   Younossi, Zobair M ^a,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c Betty and Guy Beatty Center for Integrated Research   (United States)

Author keywords

cirrhosis; cost; NAFLD; resource utilization

Indexed keywords

AGED; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITAL CHARGE; HOSPITAL PATIENT; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICARE; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; OUTPATIENT; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AMBULATORY CARE; ECONOMICS; HEALTH CARE PLANNING; INSURANCE; LIVER CIRRHOSIS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; AMBULATORY CARE; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INSURANCE BENEFITS; LIVER CIRRHOSIS; MALE; MEDICARE; NON-ALCOHOLIC FATTY LIVER DISEASE; UNITED STATES;

EID: 84975525751     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000567     Document Type: Article

References (31)

1. Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2012;2: 135-144.
2. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13:2062-2070.
3. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-2273.
4. Younossi ZM, Henry L. Economic and quality-of-life implications of non-alcoholic fatty liver disease. Pharmacoeconomics. 2015;33:1245-1253.
5. Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20:9330-9337.
6. Weiss J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int. 2014;111:447-452.
7. Golabi P, Sayiner M, Fazel Y, et al. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71.
8. Birerdinc A, Younossi Z. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease? J Hepatol. 2015;62:761-762.
9. Otgonsuren M, Estep MJ, Hossain N, et al. Single noninvasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol. 2014;29:2006-2013.
10. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of allcause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023.
11. Kelley CE, Brown AJ, Diehl AM, et al. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20:14172-14184.
12. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-665.
13. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-555.
14. Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 2012 update. Prev Chronic Dis. 2014;11:E62.
15. Hernandez C, Jansa M, Vidal M, et al. The burden of chronic disorders on hospital admissions prompts the need for new modalities of care: a cross-sectional analysis in a tertiary hospital. QJM. 2009;102:193-202.
16. Centers for Disease Control (CDC). The cost of chronic diseases and health risk behaviours. Chronic Disease Overview, 2014. Available at: www.cdc.gov/chronicdisease/overview/index.htm. Accessed May 27, 2016.
17. Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28:w822-w831.
18. Younossi ZM, Zheng L, Stepanova M, et al. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2015;49:222-227.
19. Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology. 2008;134: 85-94.
20. Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Rep. 2010;12:1-6.
21. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
22. Bambha K, Belt P, Abraham M, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769-780.
23. Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32:1407-1414.
24. Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015;31:925-937.
25. Berzigotti A, Seijo S, Reverter E, et al. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7:141-155.
26. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis. 2012;16:397-419.
27. Corrado RL, Torres DM, Harrison SA. Review of treatment options for nonalcoholic fatty liver disease. Med Clin North Am. 2014;98:55-72.
28. Younossi ZM, Otgonsuren M, Venkatesan C, et al. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62: 352-360.
29. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012; 42:563-570.
30. Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, et al. Estimation of diagnosis and treatment costs of non-alcoholic fatty liver disease: a two-year observation. Hepat Mon. 2013; 13:e7382.
31. Younossi ZM, Zheng L, Stepanova M, et al. Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open. 2014;4:e004318.